EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Tri‐Culture Heart‐on‐a‐Chip Platform With iPSC‐Derived Cardiac Cells for Predictive Cardiotoxicity Testing

Karine Tadevosyan, Jose Yeste, Mar Alvarez, Denise Marrero, Laura Casado-Medina, Yvonne Richaud-Patin, Olalla García-Iglesias, Jagoda Litowczenko iD, Alba Morillas Garcia, Anton Guimerà, Xavi Illa, Rosa Villa und 1 weitere

Advanced Healthcare Materials · 2026

DOI: 10.1002/adhm.202505524 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Karine Tadevosyan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell Potency Group, Regenerative Medicine Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet De Llobregat, Spain. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Myocytes, Cardiac, Cardiotoxicity, Lab-On-A-Chip Devices. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Spanish Ministry of Science, Innovation, and Universities-MICIU, Fundació La Marató de TV3, Fundació Obra Social la Caixa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug development is hindered by high attrition rates, with clinical trial failures accounting for 90% of unsuccessful candidates and 60% of R&D costs, often due to unanticipated cardiotoxicity. Existing models lack physiological relevance, particularly the vascular component critical for drug distribution and cardioprotection. To address this, we developed a heart‐on‐a‐chip (HoC) platform integrating human induced pluripotent stem cell (iPSC)‐derived cardiomyocytes, cardiac fibroblasts, and endothelial cells from a single cell line, ensuring genetic uniformity and native‐like cell‐cell interactions. The tri‐culture system maintained >90% cell viability under perfusion for 7 days and exhibited functional maturity, as demonstrated by expected chronotropic responses to the β‐agonist isoproterenol. Crucially, the inclusion of endothelial cells mitigated doxorubicin‐induced cardiotoxicity, a protective effect absent in conventional models, highlighting the endothelial layer's role in replicating in vivo drug responses. By combining physiological mimicry with scalability, this HoC platform offers a transformative tool for improving preclinical cardiotoxicity assessment and reducing reliance on animal models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Induced Pluripotent Stem CellsMyocytes, CardiacCardiotoxicityLab-On-A-Chip DevicesHumansDoxorubicinEndothelial CellsCell SurvivalIsoproterenolFibroblastsMicrophysiological Systems

Stichwörter der Autor:innen

cardiomyocytesdoxorubicin‐induced cardiotoxicityendothelial cellsinduced pluripotent stem cellsorgan‐on‐Chip

Substanzen

DoxorubicinIsoproterenol

Autor:innen und Institutionen

  • Stem Cell Potency Group, Regenerative Medicine Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet De Llobregat, Spain.
  • Program For Clinical Translation of Regenerative Medicine in Catalonia (P-[CMRC]), L'Hospitalet De Llobregat, Spain.
  • Center For Networked Biomedical Research On Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.
  • Institut De Microelectrònica De Barcelona, IMB-CNM (CSIC), Barcelona, Spain.
  • Center For Advanced Technologies, Adam Mickiewicz University, Poznań, Poland.
  • Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

ORCID-Profile: Jagoda Litowczenko, Angel Raya

Förderung

  • Spanish Ministry of Science, Innovation, and Universities-MICIU
  • Fundació La Marató de TV3
  • Fundació Obra Social la Caixa
  • María de Maeztu program for Units of Excellence
  • Direcció General de Recerca, Generalitat de Catalunya
  • 'la Caixa' Foundation
  • Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya
  • Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España

Zitieren

APA

Tadevosyan, K., Yeste, J., Alvarez, M., Marrero, D., Casado-Medina, L., Richaud-Patin, Y., García-Iglesias, O., Litowczenko, J., Garcia, A. M., Guimerà, A., Illa, X., Villa, R., & Raya, A. (2026). A Tri‐Culture Heart‐on‐a‐Chip Platform With iPSC‐Derived Cardiac Cells for Predictive Cardiotoxicity Testing. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202505524

Vancouver

Tadevosyan K, Yeste J, Alvarez M, Marrero D, Casado-Medina L, Richaud-Patin Y, et al. A Tri‐Culture Heart‐on‐a‐Chip Platform With iPSC‐Derived Cardiac Cells for Predictive Cardiotoxicity Testing. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202505524

BibTeX
@article{Tadevosyan2026,
  author = {Tadevosyan, Karine and Yeste, Jose and Alvarez, Mar and Marrero, Denise and Casado-Medina, Laura and Richaud-Patin, Yvonne and García-Iglesias, Olalla and Litowczenko, Jagoda and Garcia, Alba Morillas and Guimerà, Anton and Illa, Xavi and Villa, Rosa and Raya, Angel},
  title = {A Tri‐Culture Heart‐on‐a‐Chip Platform With iPSC‐Derived Cardiac Cells for Predictive Cardiotoxicity Testing},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.202505524}
}
Kostenlos starten →